Clinical trial
Safety Study Of Nasal HIV Vaccine Adjuvanted With LTK63
NCT00369031 · St George's, University of London, Other · Terminated
Key facts
| NCT number | NCT00369031 |
|---|---|
| Title | Safety Study Of Nasal HIV Vaccine Adjuvanted With LTK63 |
| Official title | A Phase I, Open Label, Parallel Group Trial To Evaluate Safety And Immunogenicity Of Three Nasal Immunisations Using A Fixed Dose-Level Of HIV gp140 V2 Loop Deleted Protein Adjuvanted With LTK63 Followed By Intramuscular Boosting With HIV gp140 V2 Loop Deleted Protein Adjuvanted With MF59 When… |
| Lead sponsor | St George's, University of London, Other |
| Collaborators | Richmond Pharmacology Limited Industry Novartis Vaccines European Union |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Biological |
| Interventions | Human Immunodeficiency Virus glycoprotein 140 (vaccine), HIV glycoprotein 140 + Labile Toxin mutant LTK63 adjuvant, Labile Toxin mutant LTK63 adjuvant |
| Enrollment | 31 |
| Start date | Sep 1, 2006 |
| Primary completion | Nov 1, 2007 |
| Completion | Mar 1, 2008 |
| First posted | Aug 29, 2006 |
| Last update posted | Apr 15, 2008 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: